PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom mRNA vaccine aims to stop Cancer's return after surgery
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Shenzhen Xinhe Biomedical • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 16, 2026 23:23 UTC
-
Engineered immune cells take on tough pancreatic cancer
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on pancreatic cancer cells. The goal is to see if these cells are safe and can shrink tumors in people with advanced pancreatic cancer that has not responded to standard …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 16, 2026 23:23 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study tests an experimental drug called RMC-6236 in adults with advanced solid tumors like lung, colorectal, and pancreatic cancers that have specific RAS mutations. The goal is to see if the drug is safe and tolerable, and how it works in the body. About 754 participants wi…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 16, 2026 23:22 UTC
-
Triple threat: new combo aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Can genes predict chemo success in pancreatic cancer?
Disease control Recruiting nowThis study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (lik…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Radioactive 'Bullet' injected into pancreatic tumors shows promise in early trial
Disease control Recruiting nowThis early study tests a new treatment for pancreatic cancer that cannot be surgically removed. A single injection of a radioactive implant is placed directly into the tumor, alongside standard chemotherapy. The goal is to see if this combination is safe, feasible, and can shrink…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: BetaGlue Therapeutics SpA • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Tailored vaccine aims to keep pancreatic cancer from coming back
Disease control AVAILABLEThis program offers a personalized peptide vaccine called PCNAT-01 to people with pancreatic cancer who have had surgery and finished standard chemotherapy. The vaccine is designed to train the immune system to recognize and attack any remaining cancer cells, with the goal of low…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New drug JYP0015 targets Hard-to-Treat RAS-Mutant cancers
Disease control Recruiting nowThis study tests an experimental drug called JYP0015 in adults with advanced solid tumors (pancreatic, lung, or colorectal cancer) that have a specific genetic change called a RAS mutation. The goal is to see if the drug is safe and can shrink tumors. About 210 people will take p…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug, BMS-986523, alone or with other cancer treatments, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard therapy. The main goals are to check safety and find the right dose. About 2…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 study tests a new drug called daraxonrasib, either alone or with standard chemotherapy, in people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps patients live longer or slows tumor growth. About 900 adults with a specific …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Personalized cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment using donor immune cells (CAR-NK cells) that are specially designed to attack cancer. Up to 85 adults with advanced solid tumors that have not responded to standard therapy will receive cells targeting one or two specific markers found…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug KO-2806 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called KO-2806 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer medicines. The main goals are to check safety and see if the drug can shrink tumors.
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New chemo duo aims to shrink abdominal tumors in pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemo (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will rece…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New drug STRO-004 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called STRO-004 in adults with advanced solid tumors that have not responded to other treatments. The trial has three parts: finding a safe dose of STRO-004 alone, testing that dose in more people, and combining STRO-004 with another drug (pe…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
Could a blood disorder drug boost chemo for pancreatic cancer?
Disease control Recruiting nowThis early-phase trial tests whether adding fostamatinib (a drug already approved for a blood disorder) to standard chemotherapy can help people with pancreatic cancer that can be surgically removed. About 36 adults will receive the drug combination before and after surgery. The …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have already tried at least one other treatment. The main goals are to find a safe dose and see if the drug can shrink tumors. About 27 adults w…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New hope for Hard-to-Treat cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a new drug called RMC-5127, alone or with other medicines, in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific KRAS G12V mutation. The goal is to see if the drug is safe and can shrink tumors. About 574 particip…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Engineered immune cells take on hard-to-treat pancreatic cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment made from a patient's own immune cells (NK cells) that are engineered to recognize and attack two common markers on pancreatic cancer cells. The study enrolls 42 adults with advanced pancreatic cancer that has spread or cannot be remov…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
New hope for pancreatic cancer: drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemo alone. The goal is t…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
New hope for tough pancreatic cancer? drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called BNT327 combined with chemotherapy in people with metastatic pancreatic cancer that has not been treated before. About 105 adults will take part to see if the combo can shrink tumors and control the disease. The goal is to manage the cancer, not …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 03, 2026 12:07 UTC
-
New hope for tough pancreatic cancer: experimental combo tested
Disease control Recruiting nowThis study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 01, 2026 18:06 UTC
-
New hope for tough pancreatic cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ProAgio alongside standard chemotherapy (gemcitabine and nab-paclitaxel) with or without the immunotherapy atezolizumab in people with advanced pancreatic cancer that has spread. The main goals are to find a safe dose and see how wel…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated Jun 01, 2026 18:05 UTC
-
New hope for tough pancreatic cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has spread and has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow the cancer's growth, and to check for side effects. Participa…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New scan could spot pancreatic cancer sooner
Diagnosis Recruiting nowThis study is testing a new type of PET scan called FAPI PET to see if it can detect pancreatic cancer progression or return earlier than current tests. About 35 adults with pancreatic cancer that hasn't spread will get this scan at several points during their treatment. The goal…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Diagnosis
Last updated Jun 16, 2026 23:21 UTC
-
New scan could spot pancreatic cancer spread earlier
Diagnosis Recruiting nowThis study tests a new type of PET/CT scan that uses a special tracer called [¹⁸F]FAPI-74 to see if it can better find when pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will get one dose of the tracer and then have the scan. Res…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: PHASE3 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 15, 2026 19:06 UTC
-
Revolutionary blood test could spot six cancers at once!
Diagnosis Recruiting nowThis study aims to create a simple blood test that can detect several types of digestive system cancers (like liver, pancreatic, and colon cancer) early, when they are easier to treat. Researchers will analyze tiny molecules called miRNAs in the blood of 1,000 adults—some with ca…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 15, 2026 18:54 UTC
-
Nanomechanical biopsy could revolutionize pancreatic cancer care
Diagnosis Recruiting nowThis study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: ARTIDIS AG • Aim: Diagnosis
Last updated Jun 12, 2026 12:08 UTC
-
New powder aims to ease stomach troubles in pancreatic cancer
Symptom relief Recruiting nowThis study tests a special medical food powder (Encala®) in 18 adults with pancreatic cancer who have trouble absorbing fat, causing stomach issues and weight loss. The goal is to see if the powder is easy to take and helps improve fat absorption and quality of life. Participants…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Symptom relief
Last updated Jun 16, 2026 12:53 UTC
-
Scientists hunt for new treatments for liver metastases in colorectal and pancreatic cancers
Knowledge-focused Recruiting nowThis study aims to understand why liver metastases are so deadly in colorectal and pancreatic cancers. Researchers will analyze tumors and blood from 625 participants to find new targets for immune and gene therapies. The goal is to develop better treatments for these hard-to-tre…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 16, 2026 23:20 UTC